{
  "id": 2002697,
  "title": "For Moderna, cancer vaccine results ease investor skepticism on its future as stock soars",
  "url": "https://urgent.news/2026/08/19/for-moderna-cancer-vaccine-results-ease-investor-skepticism-on-its",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-19T18:58:48.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/for-moderna-cancer-vaccine-results-ease-investor-skepticism-on-its-future-as-stock-soars/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Moderna has been saying for years that it would diversify its portfolio beyond infectious diseases. Investors were waiting for late-stage proof. On Wednesday, they got it. Moderna's shares soared to multiyear highs after disclosing",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Fortune",
        "title": "Moderna’s and Merck’s personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring",
        "url": "https://urgent.news/2026/08/19/modernas-and-mercks-personalized-mrna-vaccine-shows-real-promise",
        "published": "2026-08-19T17:47:38.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}